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ABSTRACT: The synthesis of two polyhydroxylated pyrrolidines
as 1,4-dideoxy-1,4-imino-D-arabinitol (DAB) analogues bearing a
hydrazide moiety is described. The DAB analogues act as selective
and potent inhibitors of α-mannosidase in the submicromolar
concentration ranges (Ki values ranging from 0.23 to 1.4 μM).
■ INTRODUCTION
Glycosidases represent a group of enzymes that is abundant in
essentially all living organisms, in which they catalyze the
hydrolysis of glycosidic bonds.1 Such hydrolases are, for
instance, involved in the intestinal digestion of starch, the
biosynthesis of oligosaccharide chains, and the hydrolysis of
glycoconjugates in the lysosomes. Thus, the diverse biological
roles of glycosidases have labeled glycosidase inhibitors as
attractive pharmaceutical targets.2
The most common type of glycosidase inhibitor is azasugars
(such as isofagomine (1) (Figure 1)) and iminosugars, in
which a carbon atom or the endocyclic oxygen atom in a
saccharide has been replaced by a nitrogen atom, respectively.3
Currently, three iminosugars, namely, Glyset (N-(2-hydrox-
yethyl)-1-deoxynojirimycin),4 Zavesca (N-butyl-1-deoxynojir-
imycin),5 and Galafold (1-deoxygalactonojirimycin),6 are
marketed for the treatment of type 2 diabetes, Gaucher
disease, and Fabry disease, respectively. In addition, due to
their glycosidase inhibitory properties, aza- and iminosugars
serve as lead compounds for the treatment of diseases such as
diabetes, cancer, viral infections, and lysosomal storage
disorders.7 However, in many cases, a limitation of iminosugars
as drug candidates is that they display low glycosidase
inhibition selectivity and thus they interact with glycosidases
that are not involved in the disease that they are targeted to
tackle;8 as a result, severe side effects can be triggered when
this lack of selectivity is present.
Aza- and iminosugars are believed to act as glycosidase
inhibitors due to their ability to be protonated at physiological
pH and thus resemble the charge in the transition state of
glycosidase-catalyzed cleavage of glycosidic bonds.9 Aza- and
iminosugars have therefore been used as tools to explore the
mechanism of glycosidases.10 Thus, many aza- and iminosugars
have been designed and synthesized to resemble the charge
and/or shape of the transition state of catalyzed cleavage of
glycosidic bonds.10,11 One such example is isofagomine (1),
which was found to be a very potent inhibitor of β-glucosidase
(Ki, 0.11 μM).
12 Interestingly, X-ray analysis of a cellobio-
derived isofagomine in complex with Cel5A confirmed that the
isofagomine derivative is bound to the enzyme in its
protonated form and as such establishes an ion−ion interaction
with the catalytic nucleophile.13 The importance of ion−ion
interactions between the enzyme and the inhibitor and Ganem
et al.’s hypothesis that sugar amidines behave as broad
spectrum glycosidase inhibitors because they resemble the
shape of the transition state of enzymatic cleavage of
glycosides,14 even though the full understanding of the features
of the transition state of such enzymes is missing,15 led to the
Received: May 26, 2020
Accepted: June 30, 2020
Published: July 15, 2020
Figure 1. Compounds 1−3 and the target compounds 4−6 in this
project.
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synthesis of an amidine analogue of isofagomine, namely,
isofagomidine (2).16 This compound was found to display a
very narrow glycosidase inhibitory spectrum along with a very
different glycosidase inhibition profile compared to isofago-
mine (1). Indeed, 2 was found to be a selective inhibitor (Ki,
0.75 μM) of jack-bean α-mannosidase, which is a member of
the retaining glycosidase hydrolase family 38 that includes α-
mannosidases with medicinal relevance.17 The difference in the
glycosidase inhibition profile between 1 and 2 was supported
by DFT calculations and was attributed to a very different
charge distribution within the two compounds in their
protonated forms.16
Many polyhydroxylated pyrrolidines such as 1,4-dideoxy-1,4-
imino-D-arabinitol (DAB, 3) (Figure 1) have been found to be
potent glycosidase inhibitors.7,18 In addition, many of them
inhibit a rather broad spectra of glycosidases, which has been
attributed to the flexibility of the five-membered ring system19
including, in some cases, their ability to form a half chairlike
conformation.20
DAB (3) has been found to display inhibition of various
types of α-glucosidases.21 However, it has been shown that
selectivity for other glycosidases can be achieved upon
chemical modifications.22 Thus, as part of our ongoing
research on sugar hydrazide imides,23 we wanted to investigate
whether the insertion of a hydrazide imide moiety into DAB to
obtain arabinohydrazide imides 4 and 5 would have any impact
on the inhibition profile as was the case when isofagomine (1)
was converted into its corresponding amidine 2. In this paper,
we present the synthesis of 4, 5, and 6 and DFT calculations
shedding light on their charge distribution, in addition to their
glycosidase inhibitory activity.
■ RESULTS AND DISCUSSION
The synthesis of hydrazide imides 4Cl and 5Cl commenced
from 2,3,5-tri-O-benzyl-L-xylofuranose (7) (Scheme 1), which
in turn was obtained from L-xylose in three steps by following
reported procedures.24 Thus, by following a protocol reported
by Ermert and Vasella for the synthesis of 2,3,4,6-tetra-O-
benzyl-D-glucononitrile,25 condensation of 7 with hydroxyl
amine to provide an aldoxime intermediate followed by
dehydration under Appel conditions provided nitrile 9 in
52% yield along with known L-xylonolactone 8.26 In the
subsequent step, compound 9 underwent stereospecific
hydrazidation into hydrazide 10 in 54% yield involving
triflation of the free hydroxyl group on C4 followed by
treatment with Boc-hydrazide. TFA-promoted removal of the
Boc-protective group activated the cyclization into hydrazide
imide 11 after treatment with HCl. The benzyl protective
groups were removed by palladium-catalyzed hydrogenation in
EtOH/TFA to provide hydrazide imide 4Cl after counterion
exchange with HCl. In order to exclude any unexpected
epimerization in the synthesis of 4Cl, a NOESY experiment
was conducted, which showed interaction between the protons
in the 2- and 4-position as expected. Interestingly, when the
hydrogenation time was extended from 19 to 48 h, the N-ethyl
hydrazide imide 5Cl was obtained in 85% yield. Similar N-
ethylation observations have been made both by Jensen and
co-workers27 and Sydnes and Isobe28 when ethanol was
employed as a solvent for palladium-catalyzed hydrogenation
to remove benzyl groups from iminosugars and to reduce
nitrobenzenes, respectively. In the latter case, it was proposed
that acetaldehyde was the alkylating agent formed through a β-
hydride elimination mechanism, first proposed by Sajiki and
co-workers.29
We also attempted to obtain sugar hydrazide imide 12
(Scheme 2), with a six-membered ring system. Thus, the
amino group of hydrazide 10 was benzyl-protected into
compound 13 upon reductive amination with benzaldehyde
and sodium triacetoxyborohydride. Unfortunately, TFA-
promoted removal of the Boc-protective group triggered the
cyclization into the five-membered ring system 11 and not the
six-membered ring as anticipated. We also envisaged that 4Cl
should rearrange into 12 via an imidate intermediate upon
treatment with HCl in methanol. However, when 4Cl was
treated with methanolic HCl at elevated temperature, we did
not observe any reaction. When we attempted the same
reaction in the microwave at 150 °C, we realized that 4Cl
underwent hydrolysis into the corresponding hydrazide 6HCl
in 60% yield.
Scheme 1. Synthesis of D-Arabinohydrazide Imides 4Cl and
5Cl
Scheme 2. Synthesis of Hydrazide 6HCl and Attempted
Synthesis of Hydrazide Imide 12
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Compounds 4Cl, 5Cl, and 6HCl, in addition to positive
reference compounds isofagomine (1) and 1-deoxynojirimycin
(DNJ), underwent screening as glycosidase inhibitors on a
panel of commercial glycosidases including α-glucosidase (
Saccharomyces cerevisiae), β-glucosidase (almonds), α-galacto-
sidase (green coffee beans), β-galactosidase (Aspergillus
oryzae), β-galactosidase (Escherichia coli), α-mannosidase
(jack beans), and β-mannosidase (Helix pomatia) (Table 1).
The inhibition data demonstrate clearly that the inhibition
profile for hydrazide imides 4Cl and 5Cl and compound 6HCl
is very different from that of DAB (3) with respect to β-
glucosidase activity. In contrast to 3, which behaves as a
micromolar inhibitor for β-glucosidase,22 4Cl, 5Cl, and 6HCl
display no or very low inhibition of that enzyme. Comparison
of the inhibition profiles for 4Cl and 5Cl with isofagomidine
(2) demonstrates that they are very similar and display
competitive inhibition of α-mannosidase down to the
submicromolar concentration range (Ki = 0.23 μM for 4Cl),
indicating the profit of a hydrazide imide or amidine moiety for
the binding to the enzyme. The only difference in the
inhibition profile between hydrazide imides 4Cl and 5Cl
differing in only one N-ethyl group is that the former behaves
as a competitive inhibitor for α-glucosidase in the micromolar
concentration range. Moreover, alkylation of the exocyclic
nitrogen atom furnishes a roughly 6-fold impairment in the
activity against α-mannosidase. These data mean that a high
degree of selectivity was achieved in both DAB analogues, with
a selectivity index ranging from 22 to >400; accordingly, severe
side effects derived from the unselective inhibitory profile of
many other iminosugars can be avoided. The selectivity toward
α-mannosidase inhibition by 4Cl and 5Cl is interesting from a
medicinal perspective, given that α-mannosidase is a relevant
target against tumorigenic processes.30
In order to gain more insight into the different inhibition
profile for hydrazide imides 4Cl and 5Cl compared to 6HCl,
the charge distribution within the systems 3−6 was calculated
employing the Mulliken partitioning scheme as well as by
fitting atom-centered point charges to reproduce the molecular
electrostatic potential with different schemes (Table 2). Due to
the electronic similarities between sugar amidrazones with a
pKa of 8.7 and our hydrazide imides 4 and 5,
31 we assumed
that they exist in their acidic forms in the calculations since the
glycosidase inhibitory testing was performed at 6.8 ≥ pH (6.8
for glucosidases and galactosidases and 5.6 for mannosidases).
For compounds 4−6, the atomic charge for N1 varied from
essentially zero up to positive values. The functional group
charges for NH21′ in 4 and 6 and NH1′ in 5 were less
consequent as they varied from negative up to positive values.
The most striking difference between hydrazide amides 4 and
5 compared to hydrazide 6 is that 4 and 5 host a positively
charged NH25 group in the position in which 6 contains an
oxygen (O5) with a negative atomic charge. Thus, the
difference in charge distribution between 4 and 5 compared
to 6 might be the reason for their different inhibition profiles.
In addition, because 4 and 5 possess very similar charge
distributions, we propose that the N-ethyl group of 5 disrupts
its binding to α-glucosidase as 4 binds to the same enzyme in
the micromolar concentration range. Another interesting
observation was made when 4 and 5 was compared with
isofagomidine (2),16 another α-mannosidase selective inhib-
itor; it was observed that this compound in line with 4 and 5
also possesses an exocyclic NH2 group (NH22), which hosts a
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reported for 216 have been computed with the same DFT
method but using a smaller basis set for orbital expansion (6-
31G) so that a direct comparison with the data from our
current study is somewhat hampered.
Based on the calculated charge distributions and the
coupling constants between the ring protons in the 1H NMR
spectra, we expect compounds 4Cl and 5Cl to anticipate a 3E
conformation (Figure 2). However, the coupling constants
between the ring protons in the benzyl-protected counterpart
11 are significantly smaller, which could signify an E3
conformation. A more in-depth study of conformational
dependence on charge distribution and spin−spin coupling
constants in the present molecular systems is in progress.
■ CONCLUSIONS
In the work presented herein, we obtained two 1,4-dideoxy-
1,4-imino-D-arabinitol (DAB) analogues 4Cl and 5Cl possess-
ing a hydrazide imide. These two compounds behave as
selective α-mannosidase inhibitors down to Ki = 230 nM.
When comparing 4Cl and 5Cl, two observations were made:
the N-ethyl group of 5Cl slightly impaired the inhibition of α-
mannosidase and the same group had a positive influence for
the selectivity toward α-mannosidase.
■ EXPERIMENTAL SECTION
General Information. All chemicals were obtained from
Sigma Aldrich/Merck or VWR and used as supplied. When
specified, solvents were dried by storing over 4 Å molecular
sieves. For petroleum ether (PE), the 40−65 °C fraction was
used. All reactions were carried out under a nitrogen or argon
atmosphere, unless otherwise specified. TLC analyses were
performed on Merck silica gel 60 F254 plates using UV light,
KMnO4, or heat for detection. Silica gel NORMASIL 60 40−
63 μm was used for flash column chromatography. Nuclear
magnetic resonance (NMR) spectra were recorded on a Bruker
AscendTM 400 series, operating at 400.13 MHz for 1H and
100.61 MHz for 13C in CDCl3, CD3OD, D2O, or DMSO-d6.
The assignment of signals in all NMR spectra was assisted by
conducting 1H−1H correlation spectroscopy, 1H−13C/1H−15N
heteronuclear single-quantum correlation spectroscopy, and/or
1H−13C/1H−15N heteronuclear multiple bond correlation
spectroscopy. Chemical shifts (δ) are reported in ppm relative
to an internal standard of residual chloroform (δ = 7.26 ppm
for 1H NMR; δ = 77.16 ppm for 13C NMR), residual methanol
(δ = 3.31 ppm for 1H NMR; δ = 49.00 ppm for 13C NMR),
residual dimethyl sulfoxide (δ = 2.50 ppm for 1H NMR; δ =
39.52 ppm for 13C NMR), or residual water (δ = 4.79 ppm for
1H NMR). Infrared spectroscopy (IR) was performed on a
Cary 360 FTIR spectrophotometer. High-resolution mass
spectra (HRMS) were recorded from MeOH solutions on a
JMS-T100LC AccuTOFTM in positive electrospray ionization
(ESI) mode. The microwave-assisted experiments were
performed in a CEM Focused Microwave Synthesis System,
model type Discover, operating at 0−300 W at a temperature
of 118 °C and a pressure range of 0−290 psi, with reactor vial
volumes of 10 mL.
2,3,5-Tri-O-benzyl-L-xylofuranose (7). Step 1: To a solution
of AcCl (0.29 mL, 4 mmol) in MeOH (40 mL) was added L-
xylose (3 g, 20 mmol) at rt. The reaction mixture was kept
stirring at rt for 5.5 h. The reaction mixture was then cooled to
0 °C, and pH was adjusted to ca. 9 with NaOH (1 M). The
solvent was then removed under reduced pressure, and the
resulting residue was suspended in toluene (6 × 10 mL) and
concd to dryness. Step 2: The residue from step 1 was
dissolved in dry DMF (64 mL), and NaH (4.24 g, 5.3 equiv)
was added at rt. The reaction mixture was then cooled to 0 °C
prior to addition of BnBr (11.9 mL, 5 equiv). The reaction
mixture was stirred at rt for 23 h before being extracted with
EtOAc (2 × 75 mL). The combined extracts were dried over
MgSO4 and concd in vacuo. Step 3: The residue from step 2
was dissolved in dioxane (60 mL) and HCl (60 mL, 4 M) and
stirred at 65 °C for 4 days. The reaction mixture was then
extracted with EtOAc (2 × 75 mL), and the combined organic
fractions were concentrated and subjected to flash column
chromatography (PE/EtOAc, 17:3 → 3:1). Collection of the
appropriate fractions (Rf = 0.25; PE/EtOAc, 3:1) provided
compound 7 (4.97 g, 59%) as a clear light-yellow oil. The
spectroscopic data were in full accord with the previously
reported data.23
2,3,5-Tri-O-benzyl-L-xylononitrile (9). Step 1: To a solution
of Na (315 mg, 13.7 mmol) dissolved in absolute EtOH (60
mL) was added NH2OH·HCl (1.77 g, 27.5 mmol). The
reaction mixture was stirred at rt for 5 min before a solution of
furanose 7 (1.44 g, 3.42 mmol) in absolute EtOH (11 mL) was
added. The resulting reaction mixture was stirred at rt for 1 h
before volatiles were removed by reduced pressure. To the
Table 2. Calculation of Charge Distribution within 2−6
comp. N1a/NH21
b NH21′c/NH1′d C5 NH25e/O5f
4 +0.16g −0.01 +0.54 +0.16
+0.18h 0.00 +0.22 +0.17
+0.08j +0.18 +0.27 +0.37
5 +0.07 −0.31 +0.54 +0.10
−0.05 −0.27 +0.53 +0.10
+0.23 +0.14 +0.46 +0.36
6 +0.29 −0.12 +0.50 −0.55
+0.08 −0.08 +0.51 −0.56




2j −0.1i (NH1) 0.5 (C2) 0.1 (NH22)
a4−6. b3. c4 and 6. d5. e4 and 5. f6. gHLY. hCHelpG. iMulliken. jRef
16. All calculations have been done at the B3LYP/6-311++G(d,p)
level of theory (for the geometries optimized at the same level, see the
Experimental Section for further technical details).
Figure 2. Suggested envelope conformations of compounds 4Cl, 5Cl,
and 11.
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residue were then added water (50 mL) and EtOAc (50 mL).
The two phases were separated, and the aq phase was extracted
with EtOAc (2 × 50 mL). The combined organic fractions
were dried with MgSO4, filtered, and concentrated in vacuo.
The residue (Rf = 0.4; PE/EtOAc, 3:2) was dissolved in
toluene, concentrated, and used directly in the following step.
Step 2: To a solution of PPh3 (1.89 g, 6.84 mmol, 2 equiv) in
MeCN (27 mL) at rt was added the residue from step 1. The
reaction mixture was stirred at rt for 20 min before a solution
of CBr4 (2.84 g, 8.55 mmol, 2.5 equiv) in MeCN (11 mL) was
added. The reaction mixture was then stirred at rt for 20 min
before adding a solution of PPh3 (472 mg, 1.71 mmol, 0.5
equiv) in a 1:5.5 mixture of MeCN/MeOH (45 mL). The
reaction mixture was then stirred for an additional 15 min
before the solvent was removed under reduced pressure. The
residue was subjected to flash chromatography (silica; PE/
EtOAc, 1:0 → 9:1). Collection of the first fraction (Rf = 0.6;
PE/EtOAc, 3:1) provided lactone 8 (286 mg, 20%) as a clear
colorless oil. Collection of the appropriate fractions (Rf = 0.4;
PE/EtOAc, 3:1) provided nitrile 9 (741 mg, 52%) as a clear
colorless oil. [α]D
26.6 °C −29 (c 0.5 in CHCl3); 1H NMR
(CDCl3, 400 MHz): δ = 7.37−7.24 (m, 15 H, Ar-H), 4.88 (d, J
= 11.5 Hz, 1H, CHPh), 4.82 (d, J = 11.2 Hz, 1H, CHPh), 4.60
(d, J = 11.2 Hz, 1H, CHPh), 4.55 (d, J = 11.5 Hz, 1H, CHPh),
4.45 (d, J = 1.5 Hz, 2H, CHPh), 4.43 (d, J = 6.6 Hz, 1H, H-2),
4.11 (m, 1H, H-4), 3.88 (dd, J3,4 = 2.9 Hz, J3,2 = 6.6 Hz, 1H, H-
3), 3.45 (ddd in 1:2:2:1 ratio, J5a,4 = 6.0 Hz, J = 9.5 Hz, J5b,4 =
16.3 Hz, 2H, H-5), 2.29 (d, J = 7.2 Hz, 1H, OH); 13C NMR
(CDCl3, 100 MHz): δ = 137.7 (Ar), 137.3 (Ar), 135.7 (Ar),
128.8−128.0 (Ar), 116.8 (CN), 78.1 (C-3), 75.2 (CH2), 73.4
(CH2), 73.0 (CH2), 70.4 (C-5), 69.6 (C-4), 69.3 (C-2). IR
(ATR, cm−1): 3470, 3065, 3032, 2920, 2870, 1955, 1882,
1812, 1554, 1497, 1455, 1398, 1353, 1250, 1210, 1096, 1028,
1002, 913, 821, 738; HRMS (ESI): m/z [M + Na]+ calcd for
C26H27O4NNa, 440.1832; found, 440.1827. Data for 8:
1H
NMR (CDCl3, 400 MHz): δ = 7.36−7.25 (m, 15H), 5.05 (d, J
= 11.5 Hz, 1H), 4.60−4.50 (m, 5H), 4.37 (t, J = 7.1 Hz, 1H),
3.77 (dd, J = 2.9 Hz, J = 10.8 Hz, 1H), 3.71 (dd, J = 3.2 Hz, J =
10.8 Hz, 1H). 13C NMR (CDCl3, 100 MHz): δ = 173.5, 137.8,
137.4, 137.2, 128.7−127.7, 79.5, 77.4 (2 × C), 73.8, 72.8, 72.7,
67.3. The spectroscopic data for compound 8 were in full
accord with the previously reported data.26
2,3,5-Tri-O-benzyl-4-(2-tert-butoxycarbonyl)hydrazinyl-4-
deoxy-D-arabinonitrile (10). Step 1: To a solution of alcohol 9
(200 mg, 0.48 mmol) in DCM (4 mL) at 0 °C was added
pyridine (0.1 mL, 1.24 mmol, 2.6 equiv). The mixture was
stirred for 10 min prior to dropwise addition of triflic
anhydride (0.1 mL, 0.60 mmol, 1.25 equiv). The reaction
mixture was further stirred at 0 °C for 15 min before being
diluted with DCM (20 mL), washed with cold HCl (10 mL, 1
M) and saturated aq NaHCO3 (12 mL), dried over MgSO4,
and filtered. The residue (Rf = 0.71; PE/EtOAc, 7:3) was
concentrated under reduced pressure and used directly in the
following step. Step 2: To a solution of the triflate from step 1
in THF (1.5 mL) at 0 °C was added tert-butylcarbazate (320
mg, 2.42 mmol, 5 equiv). The reaction mixture was stirred at rt
for 44 h before volatiles were removed under reduced pressure.
The residue was subjected to flash column chromatography
(PE/EtOAc, 95:5 → 9:1). Collection of the appropriate
fractions (Rf = 0.28; PE/EtOAc, 9:1) provided hydrazide 10
(138 mg, 54%) as a clear white oil. 1H NMR (CDCl3, 400
MHz): δ = 7.36−7.28 (m, 15H), 5.77 (brs, 1H, NH), 4.88 (d,
J = 11.5 Hz, 1H, CHPh), 4.84 (d, J = 11.1 Hz, 1H, CHPh),
4.73 (d, J2,3 = 3.7 Hz, 1H, H-2), 4.64 (d, J = 11.1 Hz, 1H,
CHPh), 4.57 (d, J = 11.5 Hz, 1H, CHPh), 4.52 (d, J = 11.8 Hz,
1H, CHPh), 4.45 (d, J = 11.8 Hz, 1H, CHPh), 3.82 (dd, J2,3 =
3.7 Hz, J3,4 = 7.0 Hz, 1H, H-3), 3.71 (dd, J5a,4 = 4.4 Hz, J5a,5b =
9.7 Hz, 1H, H-5a), 3.60 (dd, J5b,4 = 5.7 Hz, J5b,5a = 9.7 Hz, 1H,
H-5b), 3.27 (ddd, J4,5a = 4.4 Hz, J4,5b = 5.7 Hz, J4,3 = 7.0 Hz,
1H, H-4), 1.44 (s, 9H); 13C NMR (CDCl3, 100 MHz): δ =
156.7 (CO), 137.9 (Ar), 137.5 (Ar), 136.0 (Ar), 128.8−
128.0 (Ar), 117.8 (CN), 80.6 (C(CH3)3), 78.1 (C-3), 74.9
(CH2), 73.5 (CH2), 72.9 (CH2), 68.3 (C-2), 67.8 (C-5), 60.5
(C-4), 28.4 (CH3); IR (ATR, cm
−1): 3339, 3014, 2979, 2929,
2870, 1718, 1497, 1454, 1393, 1367, 1249, 1216, 1157, 1088,
1073, 1028; HRMS (ESI): m/z [M + H]+ calcd for
C31H38O5N3, 532.2806; found, 532.2802.
(2R,3R,4R)-1-Amino-3,4-bis(benzyloxy)-2-((benzyloxy)-
methyl)-5-iminopyrrolidin Hydrochloride (11). To a solution
of nitrile 10 (140 mg, 0.26 mmol) in DCM (10 mL) at rt was
added TFA (2 mL) dropwise. The reaction mixture was stirred
at rt for 3 h before toluene was added, and the volatiles were
removed in vacuo. The residue was then purified by flash
column chromatography (DCM/MeOH (0.1 M HCl), 94:6).
Collection of the appropriate fractions (Rf = 0.35; DCM/
MeOH (0.1 M HCl), 9:1) provided the title compound (98.3
mg, 88%) as a clear colorless oil. [α]D
27.2 °C −11 (c 0.20 in
MeOH); 1H NMR (MeOD, 400 MHz): δ = 7.34−7.25 (m,
15H, ArH), 4.82 (d, J4,3 = 3.9 Hz, 1H, H-4), 4.73 (d, J = 11.5
Hz, 1H, CHPh), 4.63 (d, J = 11.5 Hz, 1H, CHPh), 5.59 (d, J =
11.8 Hz, 1H, CHPh), 4.48 (bs, 2H, CHPh), 4.47 (d, J = 11.8
Hz, 1H, CHPh), 4.25 (t, J = 3.9 Hz, 1H, H-3), 3.96 (m, 1H, H-
2), 3.89 (dd, JCHaOH,2 = 3.4 Hz, JCHaOH,CHbOH = 10.9 Hz, 1H,
CHaOH), 3.63 (dd, JCHbOH,2 = 3.2 Hz, JCHbOH,CHaOH = 10.9
Hz, 1H, CHbOH); 13C NMR (MeOD, 100 MHz): δ = 166.7
(CN), 138.9 (Ar), 138.4 (Ar), 138.1 (Ar), 129.6−129.1
(Ar), 82.3 (C-4), 79.6 (C-3), 74.2 (CH2), 74.0 (CH2),
73.3(CH2), 71.0 (C-2), 66.3 (CH2OH); IR (ATR, cm
−1):
3029, 2929, 2110, 1953, 1882, 1811, 1702, 1624, 1495, 1453,
1362, 1261, 1209, 1121, 1099, 1063, 1028, 971, 915; HRMS
(ESI): m/z [M + H]+ calcd for C26H30O3N3, 432.2282; found,
432.2276.
(2R,3R,4R)-1-Amino-3,4-dihydroxy-2-(hydroxymethyl)-5-
iminopyrrolidine Hydrochloride (4Cl). A degassed suspension
of per-O-benzylated hydrazide imide 11 (98 mg, 0.23 mmol)
and Pd/C (280 mg) in EtOH/TFA (10 mL, 9:1) was
hydrogenated at 1 atm at rt for 19 h. The reaction mixture was
then filtered through Celite and washed with EtOH before the
filtrate was concentrated in vacuo. The residue was dissolved in
methanolic HCl (0.5 M) and evaporated to dryness to afford
the HCl salt. The salt residue was purified by flash column
chromatography (MeCN/H2O, 92:8). Collection of the
appropriate fractions (Rf = 0.42; MeCN/H2O (0.1 M HCl),
85:15) provided pyrrolidine 4Cl (40 mg, 90%) as a yellow
solid; mp 156.0−156.2 °C (decomposes); [α]D27.2 °C − 5.7 (c
0.35 in MeOH); 1H NMR (D2O, 400 MHz): δ = 4.83 (d, J4,3 =
7.0 Hz, 1H, H-4), 4.27 (t, J = 7.0 Hz, 1H, H-3), 4.13 (dd,
JCHaoH,2 = 2.6 Hz, JCHaOH,CHbOH = 13.3 Hz, 1H, CHaOH), 3.87
(dd, JCHbOH,2 = 2.5 Hz, JCHbOH,CHaOH = 13.3 Hz, 1H, H-6b),
3.72 (app. dt, J2,CHOH = 2.5 Hz, J2,3 = 7.0 Hz, 1H, H-2);
13C
NMR (D2O, 100 MHz): δ = 167.4 (CN), 74.1 (C-4), 72.7
(C-3), 68.7 (C-2), 55.5 (CH2OH). IR (ATR, cm
−1): 3369,
2125, 1724, 1624, 1205, 1109, 1063 cm−1; HRMS (ESI): m/z
[M + H]+ calcd for C5H12O3N3, 162.0873; found, 162.0871.
(2R,3R,4R)-1-(Ethylamino)-3,4-dihydroxy-2-(hydroxy-
methyl)-5-iminopyrrolidine Hydrochloride (5Cl). A degassed
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suspension of pyrrolidine 11 (95 mg, 0.20 mmol) and Pd/C
(235 mg) in EtOH/TFA (2 mL, 9:1) was hydrogenated at 1
atm at rt for 48 h. The reaction mixture was then filtered
through Celite and washed with EtOH before the filtrate was
concentrated in vacuo. The residue was dissolved in
methanolic HCl (0.5 M) and evaporated to dryness to afford
the HCl salt. The salt residue was purified by flash column
chromatography (MeCN/H2O, 88:12). Collection of the
appropriate fractions (Rf = 0.44; MeCN/H2O, 9:1) provided
the title compound (39 mg, 85%) as a yellow solid; mp 130.2−
130.4 °C (decomposes); [α]D
25.2 °C + 12.0 (c 0.17 in MeOH)
1H NMR (D2O, 400 MHz): δ = 4.90 (d, J4,3 = 6.9 Hz, 1H, H-
4), 4.31 (app. t, J = 6.8 Hz, 1H, H-3), 4.07 (dd, JCHaOH,6b =
13.0 Hz, JCHbOH,2 = 2.6 Hz, 1H, CHaOH), 4.03 (dt, J2,3 = 6.7
Hz, J2,CHbOH = 2.7 Hz, J2,CHaOH = 2.6 Hz, 1H, H-2), 3.90 (dd,
JCHbOH,CHaOH = 13.0 Hz, JCHbOH,2 = 2.7 Hz, 1H, CHbOH), 3.04
(dq, J1′a,1′b = 11.7 Hz, J1′a,2′ = 7.3 Hz, 1H, H-1′a), 2.91 (dq,
J1′b,1′a = 11.7 Hz, J1′b,2′ = 7.1 Hz, 1H, H-1′b), 1.09 (app. t, J =
7.2 Hz, 3H, H-2′); 13C NMR (D2O, 100 MHz): δ = 167.9
(CN), 73.9 (C-4), 73.0 (C-3), 64.8 (C-2), 56.0 (CH2OH),
42.0 (C-7), 11.8 (C-8); IR (ATR, cm−1): 3215, 2977, 2934,
2878, 2110, 1702, 1637, 1454, 1383, 1332, 1276, 1201, 1103,
1063, 905; HRMS (ESI): m/z [M + H]+ calcd for C7H16O3N3,
190.1186; found, 190.1184.
(3S,4R,5R)-1-Amino-3,4-dihydroxy-5-(hydroxymethyl)-2-
pyrrolidinone Hydrochloride (6HCl). A solution of pyrrolidine
4Cl (8 mg, 0.04 mmol) in MeOH (0.05 M HCl, 1 mL) was
subjected to microwave radiation (150 °C) for 90 min. The
reaction mixture was then cooled to ambient temperature
before volatiles were removed by reduced pressure. The
residue was evaporated to dryness to afford the HCl salt. The
salt residue was subjected to gravity column chromatography
(MeCN/H2O, 98:2). Collection of the appropriate fractions
(Rf = 0.41; MeCN/H2O, 85:15) provided hydrazide amide
6HCl (4.7 mg, 60%) as a white wax. [α]D
25.5 °C − 5.1 (c 0.39 in
MeOH); 1H NMR (D2O, 400 MHz): δ = 4.31 (d, J4,3 = 7.1
Hz, 1H, H-3), 4.10 (t, J = 7.1 Hz, 1H, H-4), 4.05 (dd, JCHaOH,2
= 2.7 Hz, JCHaOH,CHbOH = 12.9 Hz, 1H, CHaOH), 3.79 (dd,
JCHbOH,2 = 2.5 Hz, JCHbOH,CHaOH = 12.9 Hz, 1H, CHbOH), 3.47
(m, 1H, H-5); 13C NMR (D2O, 100 MHz): δ = 172.5 (C
O), 75.2 (C-3), 72.3 (C-4), 65.3 (C-5), 57.2 (CH2OH); IR
(ATR, cm−1): 3295, 2926, 2855, 2358, 1699, 1455, 1349,
1261, 1200, 1095, 909. LRMS (ESI): m/z [M + H]+ calcd for
C5H11O4N2, 163.0719; found, 163.0721.
2,3,5-Tri-O-benzyl-4-(1-N-benzyl-(2-tert-butoxycarbonyl)-
hydrazinyl)-4-deoxy-D-arabinonitrile (13). To a solution of
compound 10 (104 mg, 0.20 mmol) in DCE was added
Na(OAc)3BH (116 mg, 2.7 equiv) followed by benzaldehyde
(0.04 mL, 2.0 equiv) and AcOH (0.07 mL, 6.2 equiv). The
reaction mixture was stirred at rt for 18 h. The reaction mixture
was then quenched with saturated aq NaHCO3 (5 mL), and
EtOAc (10 mL) was added. The two phases were separated,
and the aq phase was extracted with EtOAc (2 × 10 mL). The
combined organic fractions were evaporated to dryness in
vacuo. Excess of benzaldehyde was removed under vacuum at
60 °C for 1 h. The residue was purified by flash column
chromatography (PE/EtOAc, 9:1). Collection of the appro-
priate fractions (Rf = 0.25; PE/EtOAc, 9:1) provided
compound 13 (89 mg, 73%) as a light-yellow oil. 1H NMR
(CDCl3, 400 MHz): δ = 7.41−6.96 (m, 20H, ArH), 6.28 and
5.84 (br.s, 1.4:1, 1H, NH), 5.52 and 5.22 (br.s, 1.5:1, 1H, H-
2), 4.98 (d, J = 10.9 Hz, 1H, CHPh), 4.84 (d, J = 10.3 Hz, 1H,
CHPh), 4.60 (d, J = 10.8 Hz, 1H, CHPh), 4.58 (d, J = 10.3 Hz,
1H, CHPh), 4.49 (d, J = 11.2 Hz, 2H, 2CHPh), 4.00−3.68 (m,
5H, 2CHPh, H-5a, H-5b, H-3), 3.34 (brs, 1H, H-4), 1.32−
1.24 (m, 9H); 13C NMR (CDCl3, 100 MHz): δ = 155.9 (C
O), 137.8−136.1 (Ar), 130.0−127.5 (Ar), 118.9−118.6 (CN),
80.8 and 80.0 (C), 78.4 (C-3), 75.2 and 74.9 (CH2), 73.8 and
73.6 (CH2), 73.2 and 72.8 (CH2), 67.6 and 66.7 (C-2), 67.0
(CH2), 63.6 and 61.9 (C-5), 61.6 and 60.7 (C-4), 28.3 and
28.1 (CH3); IR (ATR, cm
−1): 3355, 3031, 2925, 2866, 1950,
1725, 1706, 1496, 1454, 1392, 1243, 1160, 1124, 1072, 1027,
913; HRMS (ESI): m/z [M + Na]+ calcd for C38H43O5N3Na,
644.3095; found, 644.3088.
Glycosidase Inhibition Assays. Inhibition assays for
glycosidases were accomplished using the methodology
reported by Bols and co-workers.32 The percentage of
inhibition was measured by preparing two 1.2 mL samples in
PS cuvettes containing 0.1 M phosphate buffer (pH 6.8 or 5.6
for mannosidases) and the corresponding o- or p-nitrophenyl-
glycopyranoside at a concentration equal to the expected value
of KM: [S] = 0.25 mM for α-glucosidase, 4.0 mM for β-
glucosidase; 0.60 mM for α-galactosidase, 0.51 mM for β-
galactosidase (E. coli), 1.5 mM for β-galactosidase (A. oryzae),
0.90 mM for α-mannosidase, and 0.58 mM for β-mannosidase.
DMSO (control) or inhibitor solution (DMSO) plus water
was added up to a constant volume of 1.14 mL. Screenings
were conducted using a 100 μM final inhibitor concentration.
Reactions were started by adding 60 μL of properly diluted
enzyme solution at 25 ± 0.1 °C or 35 ± 0.1 °C (for
mannosidases), and the formation of the corresponding o- or
p-nitrophenolate was monitored for 125 s by measuring the
increase in absorbance at 400 nm (glucosidases and α-
galactosidase) or 420 nm (β-galactosidases) for 125 s. For α-
and β-mannosidases, an aliquot (200 μL) was taken every 60 s
and added to a 1 M Na2CO3 solution (1.8 mL), and the
absorbance was measured at 400 nm over a period of 4 min.
Initial rates (slopes of the plots Abs vs t) were used for








where v0 is the reaction rate for the enzyme solution and v is
the reaction rate for the reactions incorporating an inhibitor.
DMSO concentration was maintained at 5% (v/v) of the
total assay mixture for glycosidases.
The inhibitory constants (Ki) were determined using five
different substrate concentrations, ranging from 0.25 to 4.0 KM
at a fixed inhibitor concentration (two to three different
inhibitor concentrations). The mode of inhibition was
determined using the Cornish-Bowden method,33 which
involves the use of two different plots: 1/v vs [I] (Dixon
plot) and [S]/v vs [I]. For the calculation of kinetic parameters
(KM, Vmax), a nonlinear regression analysis (least-squares fit)
was used.
Compounds 4Cl and 5Cl turned out to be competitive
inhibitors (binding only to the free enzyme), and the











Computational Details. Geometries of the investigated
molecular systems were optimized with Schlegel’s gradient
optimization algorithm.34 Subsequent to geometry optimiza-
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tion, the second derivative Hessian matrices were evaluated
analytically for the located stationary points on the explored
potential energy surfaces (PESs). The absence of negative
eigenvalues of the Hessians (and consequently, imaginary
harmonic vibrational frequencies) indicated that true minima
have been located.
Throughout the study, the hybrid HF-DFT approach was
implemented, using the combination of three-parameter
adiabatic connection exchange functional constructed by
Becke (B3)35 with the Lee−Yang−Parr correlation functional
(LYP;36 B3-LYP). The Pople-style triple-zeta quality 6-311+
+G(d,p) basis set was used for orbital expansion. Numerical
integration was performed using a pruned “ultrafine” (99,590)
grid, constituted by 99 radial shells and 590 angular points per
shell.
Charge distribution for the structure corresponding to the
located minima on the studied PESs was investigated
employing a variety of methods for computation/assignment
of atomic charges. Aside from the widely used Mulliken
partitioning scheme and the Weinhold’s natural population
analysis,37 also several electrostatic potential-based (ESP)
schemes were employed.38−41 The ESP schemes are based
on computation of molecular ESP from the DFT density
(which is an exact procedure) followed by assignment of
charges to atomic centers within the molecule, such as
reproducing the exactly computed ESP at series of chosen
points. The second segment of the overall task is a fitting
procedure. As the ESP fit does not lead to a unique solution of
the problem (neither does any of the algorithms for charge
assignments), we have used many different algorithms for
choosing the set of points for fitting the charges (MK, CHelp,
CHelpG, etc.; see the results in Table 2 within the main text).
This was done in order to get a wider overview of the
performances of different methods. We have also focused on
trends throughout the series of investigated compounds
instead of the absolute values of the charges.
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